Allergan Inc.: PharmaVitae Profile

Allergan Inc.: PharmaVitae Profile

Introduction

This analysis examines the historical and forecast performance for Allergan in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

*Benchmark Allergan's performance against key rivals in the prescription pharmaceutical sector

*Assess how the key Botox franchise stands up to the global recession and the arrival of further competitors

*Analyze the impact of Allergan's acquisition of Esprit Pharma in 2007, namely its movement into the urology therapy market

ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Executive summary 3
Quarterly news update 3
Company introduction 3
Company sales 4
Company financials 4
Key products and competitors 4
Data sourcing 4
Sales data 4
Analyst consensus 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2002-14 6
Financial performance, 2002-14 7
Allergan: PharmaVitae forecasts at a glance 8
Strategic insight 9
Allergan is highly dependent upon sales of Botox 9
Botox plays a central role in Allergan's synergistic expansion 10
SWOT analysis 12
Strengths 12
Weaknesses 13
Opportunities 14
Threats 15
Table of Contents 16
Table of figures 18
Chapter 3 Quarterly news update 19
Product developments 19
Deals and alliances 20
Product deals 20
Technology deals 21
M&A activity 21
Company announcements 22
Future product milestones 22
Chapter 4 Company introduction 23
Key findings 23
Background 24
Key corporate developments 24
M&A history 25
Acquired by SmithKline Beckman 25
Allergan spun-out from SmithKline Beckman 26
Acquisition of Oculinum 26
Divestment of Allergan Humphrey 26
Divestment of contact lens businesses 26
Five acquisitions were made in and around 1995 26
Allergan Specialty Therapeutics spun-out 26
Allergan Specialty Therapeutics re-acquired 26
Bardeen Sciences set-up 26
Advanced Medical Optics spun-out 27
Bardeen Sciences acquired 27
Oculex acquired 27
Acquistition of Inamed 27
Groupe Corneal Laboratoires acquired 27
EndoArt acquired 27
Acquisition of Esprit Pharma 28
Current corporate structure 29
Pharmaceuticals 29
Allergan Medical 29
Chapter 5 Company sales 31
Key findings 31
Prescription pharmaceutical sales and growth rate analysis, 2002-14 32
Product analysis 34
Product analysis, 2002-08 35
Product analysis, 2008-14 37
Therapy area analysis 40
Geographic analysis 43
Launch/core/expiry analysis 45
Explanation of launch/core/expiry analysis 45
Launch analysis, 2008-14 46
Core analysis, 2008-14 49
Expiry analysis, 2008-14 50
Launch/core/expiry configuration, 2008-14 52
Molecule type analysis 53
Externalization analysis 55
Chapter 6 Company financials 57
Key findings 57
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 58
Operating costs and profit analysis 60
Operating costs and profit analysis, 2002-08 61
Operating cost ratio and profit margin analysis, 2002-08 62
Operating cost ratio and profit margin analysis, 2008-14 63
Operating costs and profit analysis, 2008-14 64
Chapter 7 Key products and competitors 66
Key findings 66
Overview 67
Central nervous system 68
Botox 68
Overview 68
Sales forecast 69
Other (ophthalmology) 71
Restasis 71
Overview 71
Sales forecast 72
Lumigan franchise 73
Overview 73
Sales forecast 74
Alphagan franchise 76
Overview 76
Sales forecast 77
Ozurdex 79
Overview 79
Sales forecast 80
Ozurdex offers significant benefits over the standard of care 81
Other (skin care) 82
Latisse 82
Overview 82
Sales forecast 83
Chapter 8 Appendix 84
R&D pipeline 84
Reconciliation with reported figures 85
References 86
Abbreviations 86
Exchange rates 87
About Datamonitor 88
About Datamonitor Healthcare 88
Datamonitor consulting 88
Disclaimer 90
List of Tables
Table 1: Allergan - PharmaVitae forecasts at a glance 8
Table 2: Allergan key product developments, Q1-Q2 2009 19
Table 3: Allergan product deals and alliances, Q1-Q2 2009 20
Table 4: Allergan technology deals and alliances, Q1-Q2 2009 21
Table 5: Allergan M&A activity, Q1-Q2 2009 21
Table 6: Allergan company announcements, Q1-Q2 2009 22
Table 7: Allergan future product milestones, 2009-11 22
Table 8: Allergan product portfolio overview ($m), 2002-08 35
Table 9: Allergan product portfolio overview ($m), 2008-14 37
Table 10: Allergan prescription pharmaceutical sales by therapy area ($m), 2008-14 42
Table 11: Allergan prescription pharmaceutical sales by geographic region ($m), 2008-14 44
Table 12: Allergan launch portfolio overview ($m), 2008-14 46
Table 13: Allergan core portfolio overview ($m), 2008-14 49
Table 14: Allergan expiry portfolio overview ($m), 2008-14 50
Table 15: Allergan prescription pharmaceutical sales by molecule type ($m), 2008-14 54
Table 16: Allergan prescription pharmaceutical sales by source ($m), 2008-14 56
Table 17: Total Allergan sales by business unit ($m), 2002-08 58
Table 18: Allergan operating revenue/cost analysis ($m), 2002-08 61
Table 19: Allergan operating cost ratio analysis (% of total revenues), 2002-08 62
Table 20: Allergan operating cost ratio analysis (% of total revenues), 2008-14 63
Table 21: Allergan operating revenue/cost analysis ($m), 2008-14 64
Table 22: Key products overview 67
Table 23: Botox: overview 68
Table 24: Botox: sales forecast ($m), 2008-14 69
Table 25: Restasis: overview 71
Table 26: Restasis: sales forecast ($m), 2008-14 72
Table 27: Lumigan franchise: overview 73
Table 28: Lumigan franchise: sales forecast ($m), 2008-14 74
Table 29: Alphagan franchise: overview 76
Table 30: Alphagan franchise: sales forecast ($m), 2008-14 77
Table 31: Ozurdex: overview 79
Table 32: Ozurdex: sales forecast ($m), 2008-14 80
Table 33: Latisse: overview 82
Table 34: Latisse: sales forecast ($m), 2008-14 83
Table 35: Allergan's R&D pipeline (Phase I-registration) 84
Table 36: Total Allergan revenue by business unit and product line ($m), 2002-08 85
Table 37: Exchange rates, 2009 87
List of Figures
Figure 1: The PharmaVitae Explorer 3
Figure 2: Allergan prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6
Figure 3: Allergan's financial performance ($m), 2002-14 7
Figure 4: Allergan prescription pharmaceutical sales ($m), 2002-14 9
Figure 5: The central role of Botox in Allergan's strategic moves 10
Figure 6: Allergan SWOT analysis 12
Figure 7: Allergan's M&A history 25
Figure 8: Current corporate structure 29
Figure 9: Allergan prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 32
Figure 10: Key product sales ($m), 2002-14 34
Figure 11: Allergan key sales growth drivers and resistors ($m), 2002-08 36
Figure 12: Allergan key sales growth drivers and resistors ($m), 2008-14 38
Figure 13: Allergan prescription pharmaceutical sales by therapy area ($m), 2002-14 40
Figure 14: Allergan prescription pharmaceutical sales by geographic region ($m), 2002-14 43
Figure 15: Allergan launch/core/expiry configuration ($m), 2008-14 52
Figure 16: Allergan prescription pharmaceutical sales by molecule type ($m), 2002-14 53
Figure 17: Allergan prescription pharmaceutical sales by source ($m), 2002-14 55
Figure 18: Allergan operating revenue/cost analysis ($m), 2002-14 60
Figure 19: Mechanisms by which current treatments reduce intraocular pressure 75